Marker Therapeutics, Inc.: awarded $2,600,000 FDA grant for MT-601

What happened The company announced that it was awarded a $2,600,000 grant by the Food & Drug Administration under the FDA’s Orphan Products development program to advance its lead investigational MAR-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer. The company issued a press release dated Oct 19, 2026 reporting the award.

Key details

• Award amount: $2,600,000.
• Program: FDA’s Orphan Products development program.
• Therapy: MT-601, described as the company’s lead investigational MAR-T cell therapy for patients with locally advanced unresectable pancreatic cancer.
• Filing date: Form 8-K filed Oct 19, 2026.

Why it may matter This filing reports Item 8.01 (Other events), which covers the company’s announcement of the FDA grant to advance MT-601. A filing does not show why the insider traded or why the company acted.